Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of...
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Immune checkpoint inhibitors (ICIs) represent an important advance in the adjuvant treatment of patients with high-risk melanoma. Although the safety profile of anti-programmed cell death protein-1 (PD-1) is fairly acceptable, different immune-related adverse events (irAEs) are described. Herein we report for the first time a notably multidisciplin...
Alternative Titles
Full title
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_3140e4e3d7bb48529700ea1b69df5dc3
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3140e4e3d7bb48529700ea1b69df5dc3
Other Identifiers
ISSN
2040-6223
E-ISSN
2040-6231
DOI
10.1177/20406223211063024
